Karavasilis, Vasilios
Samantas, Epaminontas
Koliou, Georgia-Angeliki
Kalogera-Fountzila, Anna
Pentheroudakis, George
Varthalitis, Ioannis
Linardou, Helena
Rallis, Grigorios
Skondra, Maria
Papadopoulos, Georgios
Papatsibas, George
Sgouros, Joseph
Goudopoulou, Athina
Kalogeras, Konstantine T.
Dervenis, Christos
Pectasides, Dimitrios
Fountzilas, George
Funding for this research was provided by:
Pfizer Inc
Hellenic Cooperative Oncology Group (HE_R3/07)
Hellenic Study Group for Metastatic Liver Disease
Article History
First Online: 28 November 2018
Compliance with Ethical Standards
:
: This study was supported by Pfizer Inc., by an internal Hellenic Cooperative Oncology Group (HeCOG) translational research grant (HE_R3/07) and by a Hellenic Study Group for Metastatic Liver Disease grant.
: Vasilios Karavasilis is a member of the Advisory Boards of Amgen, Pfizer, Novartis, BI, Lilly, Astellas, Genesis-Pharma, and Janssen. Epaminontas Samantas is a member of the Advisory Boards of Merck, MSD, AstaZeneca, Roche, Amgen, and Genesis. George Pentheroudakis is a member of the Advisory Boards of Roche, he has received Honoraria from Roche, he has participated in a Speakers bureau of Roche and he has received grant from Amgen. George Fountzilas ia a member of the Advisory Boards of Pfizer, Sanofi and Roche and he has received Honoraria from AstraZeneca. Georgia-Angeliki Koliou, Anna Kalogera-Fountzila, Ioannis Varthalitis, Helena Linardou, Grigorios Rallis, Maria Skondra, Georgios Papadopoulos, George Papatsibas, Joseph Sgouros, Athina Goudopoulou, Konstantine T. Kalogeras, Christos Dervenis, and Dimitrios Pectasides declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.